News
FDA Approves Olaparib Combined with Abiraterone and Prednisone as First-line Treatment for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Oncologyme
/ Sep 04, 2023
Comparative Analysis of First-line vs. Second-line CDK4/6 Inhibitor Use in HR+, HER2- Advanced Breast Cancer Patients: Findings from the Phase III Sonia Trial
Oncologyme
/ Sep 04, 2023
Comparing Surgical Approaches for Low-Risk Early-Stage Cervical Cancer: An International Study by Canadian Cancer Trials Group (SHAPE)
Oncologyme
/ Aug 29, 2023
SWOG S1826: Comparing Treatment Efficacy of Nivolumab-AVD and Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma
Oncologyme
/ Aug 29, 2023
Preoperative FOLFOX noninferior to preoperative chemoradiotherapy in locally advanced rectal cancer : Phase III PROSPECT trial
Oncologyme
/ Aug 18, 2023
GeparOLA trial: Investigating the effectiveness of neoadjuvant Olaparib and Paclitaxel in treating early HER2-negative breast cancer with high homologous recombination deficiency (HRD).
May 07, 2023
In the phase II GeparOLA trial, Neoadjuvant #Olaparib plus paclitaxel was not superior to Paclitaxel-carboplatin regarding long-term outcomes in patients...
.png)